COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #154 of 257
10/6 Late treatment study
Ader et al., medRxiv, doi:10.1101/2021.01.08.20248149 (news 10/6) (Preprint)
Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial
Source   PDF   Share   Tweet
Early terminated very late stage (95% on oxygen at baseline) DISCOVERY trial. 4% more patients were on ventilation at baseline in the HCQ group.

Ader et al., 10/6/2020, Randomized Controlled Trial, multiple countries, Europe, preprint, baseline oxygen requirements 95.4%, 52 authors.
risk of death at day 29, 6.4% lower, RR 0.94, p = 1.00, treatment 11 of 145 (7.6%), control 12 of 148 (8.1%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 257 studies    Meta analysis
Please send us corrections, updates, or comments.